Monitor for additional insider selling or commentary around clinical trial progress; current activity is routine and not materially concerning given the small size relative to market cap.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 10 $38.35entry
- T+1 · 8mo ago −1.07%α −0.96% · $37.94
- T+5 · 8mo ago −14.29%α −13.38% · $32.87
- T+20 · 7mo ago −9.07%α −8.92% · $34.87
- T+60 · 6mo ago −23.18%α −34.87% · $29.46
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
A single insider sale occurred at Stoke Therapeutics, with Director Arthur A. Levin selling 605 shares for $22,264 in the past week. This transaction is part of a broader pattern of recent insider selling, with four sales totaling $1.8 million over the last 30 days. The activity represents minimal economic impact relative to the company's $1.9B market cap.
Key Financial Metrics
Key Facts
- Director Arthur A. Levin sold 605 shares at $36.80 per share for a total of $22,264
- Transaction was an open-market sale (Form 4 code 'S')
- Part of a cluster of 4 insider sales totaling $1.8M over the past 30 days
- Total recent insider selling ($1.8M) represents only 0.09% of the company's $1.9B market cap
Financial Impact
$22,264 in open-market sales by one director; $1.8M total insider sales over 30 days
Risk Factors
- Continued insider selling could signal waning confidence
- Biotech valuation sensitivity to clinical trial outcomes not reflected in this filing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (1 trades, 7d window) | cluster-STOK-1773782609580 |
Track record
18 reports on STOK
3 of 4 bullish or bearish reports moved the stock their way by T+60. Best: +17.49% at T+60 after the Aug 3, 2026 report. 4 of 5 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry price pending
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $27.02 Now $26.63 −1.44% settles Feb 12
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry price pending
- Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $26.12 Now $26.63 +1.95% settles Feb 12
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $26.07 Now $26.63 +2.15% settles Feb 3
- Oct 29, 202618d ago 8-K Neutral 5/10 Entry $26.29 Now $26.63 +1.29% settles Jan 28
- Oct 21, 202626d ago 144 Bearish 6/10 Entry $25.70 Now $26.63 −3.62% settles Jan 20
- Sep 30, 20266w ago SC 13G Neutral 4/10 Entry $26.01 Now $26.63 +2.38% settles Dec 28
- Sep 25, 20267w ago 8-K Neutral 2/10 Entry $25.50 Now $26.63 +4.43% settles Dec 22
- Aug 18, 202612w ago Insider Cluster Neutral 3/10 Entry $33.03 to $26.20 Now $26.63 −19.38% ▼ −20.68% −19.13% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers